AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:18:09 12/06/2024 am IST			5-day change	1st Jan Change
0.759 ^USD	+3.22%		-0.73%	+11.65%

13/05	AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
20/03	North American Morning Briefing : Markets on Hold -2-	DJ

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

November 22, 2022 at 02:37 am IST

On November 21, 2022, AlloVir, Inc. announced that Jeroen van Beek, the Company's Executive Vice President and Chief Commercial Officer, has resigned from the Company effective as of November 23, 2022 to pursue new opportunities. Dr. van Beek will remain available to the Company for a post-employment consulting period through December 31, 2022.

Latest news about AlloVir, Inc.

AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
North American Morning Briefing : Markets on Hold -2-	20/03	DJ
AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
North American Morning Briefing : Stock Futures -2-	21/02	DJ
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	27/12	DJ
Sector Update: Health Care	23/12	MT
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	23/12	MT
AlloVir Shares Plummet as Global Trials of Anti-Viral T-Cell Therapy to be Discontinued	23/12	MT
Top Midday Decliners	23/12	MT
Sector Update: Health Care Stocks Gain in Late Afternoon	23/12	MT
AlloVir to Review Strategic Alternatives for the Company and Its Portfolio of Virus-Specific T Cell Therapies	22/12	CI
AlloVir scraps late-stage studies testing lead cell therapy	22/12	RE
AlloVir scraps late-stage studies testing antiviral cell therapy	22/12	RE
AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	22/12	CI
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	22/12	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	22/12	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	22/12	MT
AlloVir, Inc.(NasdaqGS:ALVR) dropped from NASDAQ Biotechnology Index	15/12	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Certain Restricted Stock Units of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Certain Stock Options of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Certain Common Stock of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Transcript : AlloVir, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 04:55 PM	12/23/12
Sector Update: Health Care Stocks Declining Late Afternoon	19/23/19	MT

Chart AlloVir, Inc.

Duration

Period

More charts

Company Profile

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.7353 USD

Average target price

0.975 USD

Spread / Average Target

+32.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+11.65%	83.41M
VERTEX PHARMACEUTICALS INCORPORATED	+18.39%	125B
REGENERON PHARMACEUTICALS, INC.	+14.55%	108B
BIONTECH SE	-6.04%	23.64B
ARGENX SE	+2.39%	22.39B
GENMAB A/S	-12.11%	17.78B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-12.32%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+0.71%	13.56B
SAREPTA THERAPEUTICS, INC.	+25.80%	11.59B

Bio Therapeutic Drugs